Have an Emergency?

For urgent assistance, please contact emergency response services.

Call: 911

Product Questions?

Questions, comments or concerns about Rising Pharmaceuticals products? Contact one of our trusted professionals today.

Call (800) 521-5340

Compare Products

Compares to the labeled active ingredients in Reference Brand. The trademark or tradename referenced is NOT registered, owned or licensed by Rising Pharmaceuticals, Inc. or its affiliates.

Angiotensin II receptor antagonist drug used mainly to treat high blood pressure.

Losartan Potassium Tablets, USP Losartan Potassium Tablets, USP Losartan Potassium Tablets, USP

Losartan Potassium Tablets, USP

Compare to: Cozaar® Tablets*
Strength: 25mg | 50mg | 100mg
* Quixin® is a registered trademark of Vistakon Pharmaceuticals LLC.
This information has been designed as a quick reference. It is intended as a reference source only and not for prescribing or dispensing product. The appropriate approved prescribing information should be consulted. Images viewed herein may appear different than they do when viewing them live because of computer and/or photographic distortion. In addition, over time, some images and information for a particular product may change. For the most up-to-date product information, please contact your pharmacist or physician.
  • Hypertension
    Losartan potassium tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents, including diuretics.
  • Hypertensive Patients with Left Ventricular Hypertrophy
    Losartan potassium tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. (See PRECAUTION, Race and CLINICAL PHARMACOLOGY, Pharmacodynamics and Clinical Effects, Reduction in the Risk of Stroke, Race.)
  • Nephropathy in Type 2 Diabetic Patients
    Losartan potassium tablets are indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatine ratio ≥300 mg/g) in patients with type 2 diabetes and a history of hypertension. In this population, losartan potassium reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease (need for dialysis or renal transplantation) (see CLINICAL PHARMACOLOGY, and Clinical Effects).